News
Galecto, Inc. Reports First Quarter 2025 Financial Results and Progress on AML Treatment Development
Galecto, Inc. announced its financial results for Q1 2025, highlighting continued progress on its dual ENL-YEATS and FLT3 inhibitor, GB3226, aimed at treating acute myeloid leukemia (AML).
“During the first quarter, we continued to advance GB3226, our dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML,” said Dr. Hans Schambye, CEO of Galecto. “We continued ...
“During the first quarter, we continued to advance GB3226, our dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML,” said Dr. Hans Schambye, CEO of Galecto. “We continued ...
"During the first quarter, we continued to advance GB3226, our dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML,” said Dr. Hans Schambye, CEO of Galecto. "We continued preclinical ...
"During the first quarter, we continued to advance GB3226, our dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML," said Dr. Hans Schambye, CEO of Galecto. "We continued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback